References
Allegretti M,
Cesta MC,
Garin A and
Proudfoot AEI
(2012)
Current status of chemokine receptor inhibitors in development.
Immunology Letters
145:
68–78.
Auerbach DJ,
Lin Y,
Miao H et al.
(2012)
Identification of the platelet‐derived chemokine CXCL4/PF‐4 as a broad‐spectrum HIV‐1 inhibitor.
Proceedings of the National Academy of Sciences of the USA
109:
9569–9574.
Balkwill F
(2004)
Cancer and the chemokine network.
Nature Reviews Cancer
4:
540–550.
Benelli R,
Barbero A,
Buffa A et al.
(2000)
Distinct chemotactic and angiogenic activities of peptides derived from Kaposi's sarcoma virus encoded chemokines.
International Journal of Oncology
17:
75–81.
Bernardini G,
Gismondi A and
Santoni A
(2012)
Chemokines and NK cells: regulators of development, trafficking and functions.
Immunology Letters
145:
39–46.
Carvalho CM,
Zhang F and
Lupski JR
(2010)
Evolution in health and medicine Sackler colloquium: genomic disorders: a window into human gene and genome evolution.
Proceedings of the National Academy of Sciences of the USA
107(Suppl. 1):
1765–1771.
Colobran R,
Casamitjana N,
Roman A et al.
(2009)
Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation.
Genes and Immunity
10:
254–259.
Colobran R,
Pedrosa E,
Carretero‐Iglesia L and
Juan M
(2010)
Copy number variation in chemokine superfamily: the complex scene of CCL3L‐CCL4L genes in health and disease.
Clinical and Experimental Immunology
162:
41–52.
Chen HJ,
Edwards R,
Tucci S et al.
(2012)
Chemokine 25‐induced signaling suppresses colon cancer invasion and metastasis.
Journal of Clinical Investigation
122:
3184–3196.
Colobran R,
Pujol‐Borrell R,
Armengol MP and
Juan M
(2007a)
The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity.
Clinical and Experimental Immunology
148:
208–217.
Colobran R,
Pujol‐Borrell R,
Armengol MP and
Juan M
(2007b)
The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility.
Clinical and Experimental Immunology
150:
1–12.
Comerford I and
Nibbs RJ
(2005)
Post‐translational control of chemokines: a role for decoy receptors?
Immunology Letters
96:
163–174.
Cook DN
(1996)
The role of MIP‐1 alpha in inflammation and hematopoiesis.
Journal of Leukocyte Biology
59:
61–66.
Croudace JE,
Inman CF,
Abbotts BE et al.
(2012)
Chemokine‐mediated tissue recruitment of CXCR3+ CD4+ T‐cells plays a major role in the pathogenesis of chronic graft versus host disease.
Blood
doi:10.1182/blood-2012-02-413260.
Daley‐Bauer LP,
Wynn MG and
Mocarski ES
(2012)
Cytomegalovirus impairs antiviral CD8+ T cell immunity by recruiting inflammatory monocytes.
Immunity
37:
122–133.
Förster R,
Davalos‐Misslitz AC and
Rot A
(2008)
CCR7 and its ligands: balancing immunity and tolerance.
Nature Reviews Immunology
8:
362–371.
Gerard C and
Rollins BJ
(2001)
Chemokines and disease.
Nature Immunology
2:
108–115.
Hadeiba H,
Sato T,
Habtezion A et al.
(2008)
CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft‐versus‐host disease.
Nature Immunology
9:
1253–1260.
Holgate ST
(2012)
Innate and adaptive immune responses in asthma.
Nature Medicine
18:
673–683.
Homey B,
Alenius H,
Müller A et al.
(2002)
CCL27‐CCR10 interactions regulate T cell‐mediated skin inflammation.
Nature Medicine
8:
157–165.
Hütter G,
Nowak D,
Mossner M et al.
(2009)
Long‐term control of HIV by CCR5 Delta32/Delta32 stem‐cell transplantation.
New England Journal of Medicine
360:
692–698.
Kuhmann SE and
Hartley O
(2008)
Targeting chemokine receptors in HIV: a status report.
Annual Review of Pharmacology and Toxicology
48:
425–461.
Kunkel SL and
Godessart N
(2002)
Chemokines in autoimmunity: from pathology to therapeutics.
Autoimmunity Reviews
1:
313–320.
Langhi DM Jr and
Bordin JO
(2006)
Duffy blood group and malaria.
Hematology
11:
389–398.
Lusso P
(2006)
HIV and the chemokine system: 10 years later.
EMBO Journal
25:
447–456.
Maerki C,
Meuter S,
Liebi M et al.
(2009)
Potent and broad‐spectrum antimicrobial activity of CXCL14 suggests an immediate role in skin infections.
Journal of Immunology
182:
507–514.
Martínez‐Muñoz L,
López‐Holgado B,
Martínez AC,
Rodríguez‐Frade JM and
Mellado M
(2012)
Chemokine receptor oligomerization: a further step toward chemokine function.
Immunology Letters
145:
23–29.
Medoff BD,
Seung E,
Hong S et al.
(2009)
CD11b+ myeloid cells are the key mediators of Th2 cell homing into the airway in allergic inflammation.
Journal of Immunology
182:
623–635.
Melchjorsen J,
Sørensen LN and
Paludan SR
(2003)
Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function.
Journal of Leukocyte Biology
74:
331–343.
Milligan ED,
Sloane EM and
Watkins LR
(2008)
Glia in pathological pain: a role for fractalkine.
Journal of Neuroimmunology
198:
113–120.
Mori M,
Liu D,
Kumar S and
Huang Z
(2005)
NMR structures of anti‐HIV D‐peptides derived from the N‐terminus of viral chemokine vMIP‐II.
Biochemical and Biophysical Research Communications
335:
651–658.
Mortier A,
Van Damme J and
Proost P
(2008)
Regulation of chemokine activity by posttranslational modification.
Pharmacology and Therapeutics
120:
197–217.
Mortier A,
Van Damme J and
Proost P
(2012)
Overview of the mechanisms regulating chemokine activity and availability.
Immunology Letters
145:
2–9.
O'Boyle G,
Fox CR,
Walden HR et al.
(2012)
Chemokine receptor CXCR3 agonist prevents human T‐cell migration in a humanized model of arthritic inflammation.
Proceedings of the National Academy of Sciences of the USA
109:
4598–4603.
Pedrosa E,
Carretero‐Iglesia L,
Boada A et al.
(2011)
CCL4L Polymorphisms and CCL4/CCL4L Serum Levels Are Associated with Psoriasis Severity.
Journal of Investigative Dermatology
131:
1830–1837.
Proudfoot AE
(2006)
The biological relevance of chemokine–proteoglycan interactions.
Biochemical Society Transactions
34:
422–426.
Proudfoot AE,
Handel TM,
Johnson Z et al.
(2003)
Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines.
Proceedings of the National Academy of Sciences of the USA
100:
1885–1890.
Rankin SM
(2012)
Chemokines and adult bone marrow stem cells.
Immunology Letters
145:
47–54.
Reshef R,
Luger SM,
Hexner EO et al.
(2012)
Blockade of lymphocyte chemotaxis in visceral graft‐versus‐host disease.
New England Journal of Medicine
367:
135–145.
Springael JY,
Urizar E and
Parmentier M
(2005)
Dimerization of chemokine receptors and its functional consequences.
Cytokine and Growth Factor Reviews
16:
611–623.
Stievano L,
Piovan E and
Amadori A
(2004)
C and CX3C chemokines: cell sources and physiopathological implications.
Critical Reviews in Immunology
24:
205–228.
Strieter RM,
Burdick MD,
Gomperts BN,
Belperio JA and
Keane MP
(2005)
CXC chemokines in angiogenesis.
Cytokine and Growth Factor Reviews
16:
593–609.
Szczuciński A and
Losy J
(2007)
Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.
Acta Neurologica Scandinavica
115:
137–146.
Tachibana K,
Hirota S,
Iizasa H et al.
(1998)
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
Nature
393:
591–594.
Vischer HF,
Vink C and
Smit MJ
(2006)
A viral conspiracy: hijacking the chemokine system through virally encoded pirated chemokine receptors.
Current Topics in Microbiology and Immunology
303:
121–154.
Yang D,
Chen Q,
Hoover DM et al.
(2003)
Many chemokines including CCL20/MIP‐3alpha display antimicrobial activity.
Journal of Leukocyte Biology
74:
448–455.
Yang LL,
Ping C,
Luo S et al.
(2009)
CXCL10 gene therapy efficiently inhibited the growth of cervical carcinoma based on the antiangiogenic and antiviral activity.
Biotechnology and Applied Biochemistry
53:
209–216.
Yeganeh B,
Xia C,
Movassagh H et al.
(2012)
Emerging mediators of airway smooth muscle dysfunction in asthma.
Pulmonary Pharmacology and Therapeutics.
http://dx.doi.org/10.1016/j.pupt.2012.06.011.
Zlotnik A and
Yoshie O
(2000)
Chemokines: a new classification system and their role in immunity.
Immunity
12:
121–127.
Further Reading
Boomker JM,
de Leij LF,
The TH and
Harmsen MC
(2005)
Viral chemokine‐modulatory proteins: tools and targets.
Cytokine and Growth Factor Reviews
16:
91–103.
Fulton A (ed.)
(2009)
Chemokine Receptors in Cancer.
Totowa, NJ: Humana Press.
Mahalingam S
(2004)
Chemokines in Viral Infections.
Austin, TX: Landes Bioscience.
Oppenheim J and
Feldman M
(2001)
Cytokine Reference: Volume 1 and Volume 2.
San Diego, CA: Academic Press.
Raman D,
Sobolik‐Delmaire T and
Richmond A
(2011)
Chemokines in health and disease.
Experimental Cell Research
317:
575–589.
Schwiebert L,
Benos D and
Simon S
(2005)
Chemokines, Chemokine Receptors and Disease.
San Diego, CA: Academic Press.
Vaddi K,
Keller M and
Newton RC
(1997)
The Chemokine Factsbook.
San Diego, CA: Academic Press.
Zlotnik A and
Yoshie O
(2012)
The chemokine superfamily revisited.
Immunity
36:
705–716.